Real World Insights: Bispecific Antibodies in R/R MM : Episode 1

Meet a 76-Year-Old Patient With Late-Line R/R MM, Unsuitable For CAR T Therapy

December 13, 2024

By Douglas Sborov, MD, MS
Mary Steinbach, NP

Opinion

Video

Panelists discuss how patient 1 is a 76-year-old female with unknown- stage R-ISS, oligosecretory IgG-K/KLC MM currently treated with talquetamab. One year following the talquetamab initiation, she is in VGPR/MRD- (likely CR or sCR as IFE positive is LLC and she has KLC). To spare toxicity physicians have decreased her dosing to monthly, starting with cycle 14 day 1.

Now Viewing

EP: 1.Meet a 76-Year-Old Patient With Late-Line R/R MM, Unsuitable For CAR T Therapy

EP: 2.Role of Step-Up Dosing

EP: 3.Dosing Frequency, and Adverse Event Management With Bispecific Therapy

EP: 4.Strategies For Management of Infections

EP: 5.Optimizing Treatment Goals and Supportive Care For Relapsed/Refractory Multiple Myeloma in Older Patients

EP: 6.Meet a 55-Year-Old Who Was Refractory to or Relapsed on BCMA CAR T Therapy

EP: 7.Patient Tolerability of Talquetamab and Use of IVIG

EP: 8.Strategizing Talquetamab Use In Relapsed/Refractory Multiple Myeloma: Balancing Efficacy, Infection Control, and Next-Line Therapy

EP: 9.Meet our 61-Year-Old Patient With Late-Line R/R on a BCMA-Targeting Bispecific

EP: 10.Dosing Strategies in Different Targets Bispecifics

EP: 11.Managing CNS and Systemic Responses In R/R MM: Monitoring and Sequencing Strategies with Elranatamab and Cilta-Cel

EP: 12.Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!